An investigation on behalf of investors in Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) shares over potential wrongdoing at Eloxx Pharmaceuticals, Inc. was announced.
San Diego, CA -- (SBWIRE) -- 05/31/2019 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Eloxx Pharmaceuticals, Inc.
Investors who purchased shares of Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Eloxx Pharmaceuticals directors breached their fiduciary duties and caused damage to the company and its shareholders.
Waltham, MA based Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel ribonucleic acid for the treatment of rare and ultra-rare premature stop codon diseases. Shares of Eloxx Pharmaceuticals, Inc. (NASDAQ" ELOX) declined from $24.90 per share on June 15, 2019 to as low as $9.01 per share on May 29, 2019.
Those who purchased shares of Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels